Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
about
Targeted drugs and Psycho-oncological intervention for breast cancer patientsMajor clinical research advances in gynecologic cancer in 2016: 10-year special edition.Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgeryIndications of airway stenting for severe central airway obstruction due to advanced cancerIntegrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.Palliative chemotherapy: oxymoron or misunderstanding?Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014.Overuse of Health Care Services in the Management of Cancer: A Systematic Review.Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.Use of cannabinoids in cancer care: palliative care.Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life.Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care.Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational studyPalliative Care and Symptom Management in Older Patients with CancerA Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature.Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study.Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study.Low-value practices in oncology contributing to financial toxicity.Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial.End-of-Life Services Among Patients With Cancer: Evidence From Cancer Registry Records Linked With Commercial Health Insurance Claims.Early palliative care for adults with advanced cancer.Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities."The Talk:" Discussing Hospice Care.The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.Utilization and evaluation of noncore chemotherapy regimens within an academic medical center.Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer.Immune checkpoint inhibitors in challenging populations.Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma.The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.Association of Palliative Care Consultation With Reducing Inpatient Chemotherapy Use in Elderly Patients With Cancer in Japan: Analysis Using a Nationwide Administrative Database.End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study.Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival.Trends in end-of-life cancer care in the Medicare program.Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names.A prospective, multicenter cohort study to validate a simple performance status-based survival prediction system for oncologists.
P2860
Q26748919-6E3A49E2-1CB4-495A-A48A-CDD618054CFBQ33563963-055B971B-4087-4530-B249-AD4674499D81Q33611167-815D8593-E910-4503-9868-95BB3E1ED7BFQ33834717-82948314-769D-4968-AA0E-F7A2C874C02BQ35940367-15B657F1-3007-4E84-AFBE-B8C00EE7B620Q35965112-EE00BDA4-AD17-4AD0-B82B-9C9B66BE7416Q36093374-C27BF4C0-1FC9-4AC1-8F50-503523C49124Q36137504-B6500148-04C7-48DE-A6BC-17029AAD8320Q36338117-ADE8F839-F88F-47C2-B884-7FBECAE2627EQ36370093-659DBA72-E6DE-41DC-AF4D-AEFEEC8E10D1Q36578276-0164A814-4F66-4538-8FFE-5E6EDBA2B582Q36685147-9DA5DD05-5112-47CB-A600-05F69674FF63Q36923839-C60802FB-1CB0-40EE-915F-40A5CB4E405BQ37017029-D04EB00A-B2FC-4BD9-8A97-317AB0EF9AACQ37117859-F93F66D4-D805-4123-A266-AE12F06A5887Q37263598-9D173A1F-4946-413B-BA2F-7478A8C6862AQ37275247-4020BEA8-4A92-48FE-8ECB-2C9888EE31C0Q37334558-4100A0F7-2658-474F-BEA8-FD22E61100EEQ37636655-52AE31B7-26EA-4D08-AA5B-0209487836BFQ37655154-1B0E1868-B272-405C-8C38-26AD5FDF7B9FQ37683464-8AA99E01-873B-4A9C-A57A-D86C3C7198A4Q37694182-C83E198E-8D45-44B4-BF70-82482DC27E5FQ37720714-57B5D637-A559-4C0E-B25B-A2058368A1A8Q38387708-22A7F9B1-4912-498D-B48D-12FC47C5129BQ38655238-756D1570-C110-4EA7-A0FE-1E4ABE5FC58EQ38730886-49C7F3CF-C99B-4293-AFD4-84466401D067Q38832236-9B992E77-EA06-434A-9509-712DD6770022Q38857926-5779C5C4-0A4A-412A-8B82-997A3F4D2B55Q38885867-55DF0075-372A-43E0-AD23-FFA344B0B8C4Q38889132-93100B5A-3058-4D35-AB32-54462E555547Q38910410-6E10B618-3B2B-4F74-AE2D-4E9D6E7647D5Q38939708-B3BB17F6-E032-4119-A625-0E5682FED730Q39404719-71A7F077-92F7-4154-8FC4-D263EC422D0FQ39446746-BC858679-858B-4733-93E8-56BE76F35EA7Q39747965-8325D792-1228-45C8-B266-AA430C7BB1A5Q39869759-22C94251-975C-4B4A-9E70-39C46703571DQ39984567-6C43ECE6-D77B-43F6-AE4B-0C975C16D994Q40091026-BA8E67A2-BFAF-4004-B3D3-2F677B7D643CQ40183498-169F5238-BF46-4B90-9003-FCBC91C5246CQ40437357-2571D250-7CFD-4461-B200-D190C95EC884
P2860
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@ast
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@en
type
label
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@ast
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@en
prefLabel
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@ast
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@en
P2093
P2860
P1433
P1476
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
@en
P2093
Alfred I Neugut
Bryan J Schneider
David A Berlin
Holly G Prigerson
Kerin B Adelson
M Carrington Reid
M Elizabeth Paulk
Manish A Shah
Paul K Maciejewski
P2860
P304
P356
10.1001/JAMAONCOL.2015.2378
P577
2015-07-23T00:00:00Z